Press Releases Quanterix Corporation

Equities

QTRX

US74766Q1013

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
5.060 ^USD	-4.71%		-22.75%	-20.44%

Mar. 02	Quanterix Corporation, Q4 2025 Earnings Call, Mar 02, 2026
Mar. 02	Quanterix Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

Press Releases

Mar. 02	Quanterix : Q4-25 Earnings Presentation-FINAL	PU
Mar. 02	Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025	BU
Mar. 02	Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide	BU
Feb. 26	Quanterix to Participate in Upcoming Investor Conferences	BU
Feb. 23	Quanterix to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026	AQ
Feb. 20	Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026	BU
Feb. 03	Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection	BU
Jan. 21	Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling	BU
Jan. 19	Quanterix Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
Jan. 16	Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
Jan. 08	Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026	BU
Dec. 22	Quanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence	BU
Nov. 20	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth	BU
Nov. 17	Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring	BU
Nov. 10	Quanterix : QTRX Q3-25 Earnings Presentation 11.10.2025	PU
Nov. 10	Quanterix Releases Financial Results for the Third Quarter of 2025	BU
Nov. 03	Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025	BU
25-09-08	Quanterix : YKL-40 Emerges as a Key Indicator of Neuroinflammatory-Driven Tau Pathology and Brain Atrophy in Alzheimer’s Disease	PU
25-08-21	Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit	BU
25-08-11	Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference	BU
25-08-07	Quanterix : QTRX Q2-25 Earnings Presentation 8.7.2025	PU
25-08-07	Quanterix Releases Financial Results for the Second Quarter of 2025	BU
25-08-04	Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025	BU
25-08-04	Quanterix Announces Cooperation Agreement with Kent Lake Capital	BU
25-07-28	Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC	BU